SCHEMBL12852245

SCHEMBL12852245

O=C(CCC(COCC(COCC(CCC(=O)CCN1C(=O)C=CC1=O)CC(=O)CCN1C(=O)C=CC1=O)CC(=O)CCN1C(=O)C=CC1=O)CC(=O)CCN1C(=O)C=CC1=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.38
PTGS1 P23219 4/20 0.36
PTGS2 P35354 4/20 0.36
FAAH O00519 2/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSP90AA1 P07900 1/20 0.33
TLR9 Q9NR96 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
XBP1 P17861 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GPR35 Q9HC97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6727209 0.95 MGLL (0.37) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL6727205 0.88 PTGS1 (0.42) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL29044909 0.74 MGLL (0.54) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL16405262 0.74 MGLL (0.54) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL23870259 0.72 PTGS1 (0.44) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL6727206 0.69 MGLL (0.33) MGLLPTGS1PTGS2FAAH
SCHEMBL16405264 0.69 PTGS1 (0.63) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL17570363 0.69 PTGS1 (0.48) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL19546603 0.68 MGLL (0.52) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL6727208 0.66 PTGS1 (0.46) MGLLPTGS1PTGS2FAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807693-B2 Apelin polypeptides AMGEN INC. (US) 2023-11-07 US disclosed
US-20170107255-A1 APELIN POLYPEPTIDES AMGEN INC. (US) 2017-04-20 US disclosed
US-20160067347-A1 APJ RECEPTOR AGONISTS AND USES THEREOF AMGEN INC. (US) 2016-03-10 US disclosed
US-20130209466-A1 COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS AMGEN INC. (US) 2013-08-15 US disclosed
US-8420779-B2 Compositions and methods for producing bioactive fusion proteins AMGEN INC. (US) 2013-04-16 US disclosed
US-8288351-B2 Antagonists of the bradykinin B1 receptor AMGEN INC. (US) 2012-10-16 US disclosed
US-8278280-B2 Antagonists of the bradykinin B1 receptor AMGEN INC. (US) 2012-10-02 US disclosed
US-7605120-B2 peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis AMGEN INC. (US) 2009-10-20 US disclosed
US-20090137483-A1 Antagonists of the bradykinin B1 receptor AMGEN INC. 2009-05-28 US disclosed
US-20090137452-A1 Antagonists of the bradykinin B1 receptor AMGEN INC. 2009-05-28 US disclosed
US-20090118181-A1 Compositions and methods for producing bioactive fusion proteins AMGEN INC. 2009-05-07 US disclosed
US-20090048149-A1 Antagonists of the bradykinin B1 receptor AMGEN INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048149-A1 Antagonists of the bradykinin B1 receptor BDKRB1, BDKRB2, LTB4R MGLL 2155/4885PTGS1 220/4885PTGS2 654/4885
US-20090118181-A1 Compositions and methods for producing bioactive fusion proteins HGFAC, HDGF, GRB2 MGLL 4489/4885PTGS1 4059/4885PTGS2 4404/4885
US-20090137452-A1 Antagonists of the bradykinin B1 receptor BDKRB1, BDKRB2, LTB4R MGLL 2515/4885PTGS1 389/4885PTGS2 817/4885
US-20090137483-A1 Antagonists of the bradykinin B1 receptor BDKRB1, BDKRB2, AVPR1B MGLL 3049/4885PTGS1 296/4885PTGS2 664/4885
US-20130209466-A1 COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS HGFAC, HDGF, GRB2 MGLL 4489/4885PTGS1 4059/4885PTGS2 4404/4885
US-20170107255-A1 APELIN POLYPEPTIDES APLNR, FABP3, AP3B1 MGLL 3340/4885PTGS1 3535/4885PTGS2 3850/4885
US-11807693-B2 Apelin polypeptides APLNR, FABP3, AP3B1 MGLL 3340/4885PTGS1 3535/4885PTGS2 3850/4885
US-20160067347-A1 APJ RECEPTOR AGONISTS AND USES THEREOF APLNR, FABP3, AP2B1 MGLL 3108/4885PTGS1 2699/4885PTGS2 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.